Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Payables (2019 - 2025)

Revolution Medicines (RVMD) has 7 years of Payables data on record, last reported at $64.6 million in Q4 2025.

  • For Q4 2025, Payables rose 18.72% year-over-year to $64.6 million; the TTM value through Dec 2025 reached $64.6 million, up 18.72%, while the annual FY2025 figure was $64.6 million, 18.72% up from the prior year.
  • Payables reached $64.6 million in Q4 2025 per RVMD's latest filing, down from $74.8 million in the prior quarter.
  • Across five years, Payables topped out at $74.8 million in Q3 2025 and bottomed at $9.6 million in Q1 2021.
  • Average Payables over 5 years is $32.2 million, with a median of $26.9 million recorded in 2024.
  • Peak YoY movement for Payables: fell 17.45% in 2024, then surged 206.06% in 2025.
  • A 5-year view of Payables shows it stood at $14.1 million in 2021, then surged by 51.57% to $21.3 million in 2022, then surged by 190.0% to $61.8 million in 2023, then dropped by 11.91% to $54.4 million in 2024, then grew by 18.72% to $64.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Payables were $64.6 million in Q4 2025, $74.8 million in Q3 2025, and $56.8 million in Q2 2025.